JP4370683B2 - そう痒疾患の検査方法 - Google Patents

そう痒疾患の検査方法 Download PDF

Info

Publication number
JP4370683B2
JP4370683B2 JP2000135043A JP2000135043A JP4370683B2 JP 4370683 B2 JP4370683 B2 JP 4370683B2 JP 2000135043 A JP2000135043 A JP 2000135043A JP 2000135043 A JP2000135043 A JP 2000135043A JP 4370683 B2 JP4370683 B2 JP 4370683B2
Authority
JP
Japan
Prior art keywords
opioid
pruritus
receptor
disease
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000135043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001318095A (ja
JP2001318095A5 (cg-RX-API-DMAC7.html
Inventor
裕生 熊谷
享男 猿田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to JP2000135043A priority Critical patent/JP4370683B2/ja
Priority to US09/704,319 priority patent/US6984493B1/en
Priority to CA002324982A priority patent/CA2324982A1/en
Publication of JP2001318095A publication Critical patent/JP2001318095A/ja
Publication of JP2001318095A5 publication Critical patent/JP2001318095A5/ja
Application granted granted Critical
Publication of JP4370683B2 publication Critical patent/JP4370683B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G01N2333/675—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin beta-Endorphins

Landscapes

  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000135043A 2000-05-08 2000-05-08 そう痒疾患の検査方法 Expired - Fee Related JP4370683B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000135043A JP4370683B2 (ja) 2000-05-08 2000-05-08 そう痒疾患の検査方法
US09/704,319 US6984493B1 (en) 2000-05-08 2000-11-02 Method for examining the involvement of opioid peptides in prurtis
CA002324982A CA2324982A1 (en) 2000-05-08 2000-11-02 Method for examining disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000135043A JP4370683B2 (ja) 2000-05-08 2000-05-08 そう痒疾患の検査方法

Publications (3)

Publication Number Publication Date
JP2001318095A JP2001318095A (ja) 2001-11-16
JP2001318095A5 JP2001318095A5 (cg-RX-API-DMAC7.html) 2007-10-18
JP4370683B2 true JP4370683B2 (ja) 2009-11-25

Family

ID=18643206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000135043A Expired - Fee Related JP4370683B2 (ja) 2000-05-08 2000-05-08 そう痒疾患の検査方法

Country Status (3)

Country Link
US (1) US6984493B1 (cg-RX-API-DMAC7.html)
JP (1) JP4370683B2 (cg-RX-API-DMAC7.html)
CA (1) CA2324982A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324742B2 (en) 2018-03-08 2022-05-10 Victoria Link Ltd. Treatment of demyelinating diseases

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005011113D1 (de) * 2004-03-30 2009-01-02 Toray Industries Morphinanderivate als mittel gegen juckreiz
KR101334401B1 (ko) 2006-04-11 2013-11-29 한국생명공학연구원 아토피 피부 질환의 기전을 모니터링 할 수 있는 아토피피부 질환의 진단 또는 치료용 마커 단백질
KR101257307B1 (ko) 2006-05-22 2013-04-23 한국생명공학연구원 인간 혈청 프로테옴에서 발굴한 아토피 피부 질환의 기전을모니터링 할 수 있는 아토피 피부 질환의 진단 또는치료용 마커 단백질
WO2011049433A1 (en) * 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
KR20150003059A (ko) * 2013-06-28 2015-01-08 김종배 뇨 중 글리아돌핀(Gliadorphin) 농도 측정을 위한 면역분석법
CN118512451A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324742B2 (en) 2018-03-08 2022-05-10 Victoria Link Ltd. Treatment of demyelinating diseases
US12318380B2 (en) 2018-03-08 2025-06-03 Victoria Link Ltd. Treatment of demyelinating diseases

Also Published As

Publication number Publication date
CA2324982A1 (en) 2001-11-08
JP2001318095A (ja) 2001-11-16
US6984493B1 (en) 2006-01-10

Similar Documents

Publication Publication Date Title
Nilsson et al. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries
Carrizo et al. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion
SAKAI et al. Desmopressin Stimulation Test for Diagnosis of ACTH-Dependent Gushing's Syndrome
TWI907406B (zh) 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
Chang et al. TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor
US6984493B1 (en) Method for examining the involvement of opioid peptides in prurtis
JP2024037767A (ja) 改変型線維芽細胞成長因子21(fgf-21)を用いる非アルコール性脂肪性肝炎(nash)の処置方法
Sumino et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women
JP2003102485A (ja) 創傷治癒バイオマーカー
WO2012068491A1 (en) Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
KR20180004816A (ko) Th2-유도된 천식의 치료에 사용하기 위한 gata-3 저해제
Lewis et al. On βH-Leu5-endorphin and schizophrenia
EP4058005B1 (en) Hydroxyureamethyl acylfulvene for use in treating rhabdoid tumors
US11304938B2 (en) Compositions and methods for treating chemotherapy resistant cancer
US20080318241A1 (en) Methods and Systems for Detecting Antiangiogenesis
EP2488198B1 (en) Treatment and diagnosis of autoimmune disorders
CN115969839A (zh) 金合欢素或金合欢素水溶性前药在制备防治免疫性心肌炎药物中的应用
CN114107474B (zh) Anxa6多态性位点作为基因标志物以及和甲氨蝶呤联合的银屑病试剂盒
EP4274662A2 (en) Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
EP1412503B1 (en) A fusion protein
JPH111500A (ja) 新規化合物
US7947458B1 (en) Placental human neurokinin B precursor
US20030224455A1 (en) Method for the diagnosis of heart diseases
ES2304818B1 (es) Metodos para el diagnostico y pronostico de las enfermedades desmielinizantes y para el desarrollo de medicamentos contra las enfermedades desmielinizantes.
JP2008541026A (ja) 樹状細胞における受容体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20000607

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20000607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090811

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090824

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120911

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120911

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees